Tularik Announces Departure of Andrew J. Perlman, EVP
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Feb. 5, 2002-- Tularik Inc. (Nasdaq:TLRK - news) today announced that Andrew J. Perlman, M.D., Ph.D. has resigned his position as Executive Vice President in order to join Affymax, Inc., a private drug-discovery company, as Chief Executive Officer.
``Andy is an esteemed colleague and a close personal friend who will be missed by the entire Tularik team,'' said David V. Goeddel, Ph.D., Tularik's CEO. ``Over the past nine years, his contributions have helped Tularik become an integrated drug discovery and development company. Although we are sad to see him go, we understand his decision to pursue this opportunity and we wish him great success.'' |
